What is CONDOLIASE used for?

CONDOLIASE is indicated for Disorder of lumbar disc.

Who makes CONDOLIASE?

CONDOLIASE is developed by Seikagaku Corporation.

What development phase is CONDOLIASE in?

CONDOLIASE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

CONDOLIASE

Seikagaku Corporation · FDA-approved active Enzyme Quality 13/100

At a glance

Generic name	CONDOLIASE
Sponsor	Seikagaku Corporation
Modality	Enzyme
Therapeutic area	Pain
Phase	FDA-approved

Approved indications

Disorder of lumbar disc

Common side effects

No common side effects on file.

Key clinical trials

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study) (PHASE3)
A Study of SI-6603 in Patients With Lumbar Disc Herniation (PHASE3)
A Study of SI-6603 in Patients With Lumbar Disc Herniation (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CONDOLIASE CI brief — competitive landscape report
CONDOLIASE updates RSS · CI watch RSS
Seikagaku Corporation portfolio CI